B. Riley Comments on Vaxart’s Q1 Earnings (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT) – Analysts at B. Riley lifted their Q1 2025 earnings estimates for shares of Vaxart in a report released on Wednesday, March 26th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their prior forecast of ($0.09). B. Riley currently has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Vaxart’s current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart’s Q2 2025 earnings at ($0.08) EPS and Q3 2025 earnings at ($0.07) EPS.

Vaxart (NASDAQ:VXRT) last issued its earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The firm had revenue of $15.19 million for the quarter, compared to analysts’ expectations of $15.68 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.

Vaxart Price Performance

NASDAQ VXRT opened at $0.42 on Monday. Vaxart has a 1-year low of $0.42 and a 1-year high of $1.34. The firm has a market capitalization of $96.01 million, a P/E ratio of -1.03 and a beta of 1.69. The business’s 50-day simple moving average is $0.62 and its 200-day simple moving average is $0.69.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Graham Capital Management L.P. increased its position in shares of Vaxart by 155.8% in the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 32,482 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 35,213 shares during the period. Invesco Ltd. boosted its position in Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 24,803 shares during the period. XTX Topco Ltd raised its position in Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 122,387 shares during the period. Finally, Bank of America Corp DE raised its position in Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 17,942 shares during the period. 18.05% of the stock is owned by institutional investors and hedge funds.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.